Lexeo Therapeutics, Inc. (LXEO) Tops Q4 EPS by 59c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. STX
3. KIDS
4. BA
5. HOOD
6. NXPI
7. CSGP
8. MANH
9. BKR
10. RCL

Go back to Lexeo Therapeutics, Inc. (LXEO) Tops Q4 EPS by 59c

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

March 30, 2026 4:06 PM EDT

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026

First CMC Development and Readiness Program (CDRP) meeting for LX2006 in Q1 2026; aligned with FDA on flexible approach to process validation such as reduced PPQ manufacturing batches

Late-breaking oral presentations at the American College of Cardiology (ACC) Annual Meeting demonstrate continued, encouraging efficacy and safety data across LX2006 and LX2020 programs

Established research collaboration with Johnson & Johnson to explore... More